Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C

Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C

Submitted by admin on February 24, 2014 - 9:55am
Source: 
Yahoo
News Tags: 
daclatasvir
breakthrough therapies
FDA
Bristol-Myers Squibb
hepatitis C
Headline: 
Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C

Do Not Allow Advertisers to Use My Personal information